Combinations of antibodies selective for DR5 and other therapeutic agents
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
1. A composition comprising (a) a soluble antibody that specifically binds TRAIL receptor DR5 and (b) one or more therapeutic agents, wherein the antibody is present in an amount sufficient to kill target cells expressing DR5, wherein the antibody induces cell death of target cells expressing DR5 in vitro in the absence of crosslinking by a secondary antibody and at concentrations less than 1 μg/ml, wherein the antibody induces cell death of target cells in vivo and wherein the antibody does not bind TRAIL receptor DR4, DcR1 or DcR2.
2. The composition of claim 1 , wherein the therapeutic agent or agents are selected from the group consisting of chemotherapeutic agents, apoptosis-inducing compounds, members of the TNF family, anti-inflammatory agents, anti-viral, anti-retroviral, anti-opportunistic agents, antibiotics, immunosuppressive agents, immunoglobulins, antimalarial agents, disease modifying anti-rheumatic drug, cytokines, chemokines, growth factors, and second antibodies that promotes apoptosis or blocks proliferation of the target cells.
3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
4. A method of selectively inducing apoptosis in target cells expressing DR5, comprising the steps of (a) contacting the target cells with a soluble antibody that specifically binds TRAIL receptor DR5 and (b) contacting the target cells with a therapeutic quantity of one or more therapeutic agents, wherein the antibody is present in an amount sufficient to kill target cells expressing DR5, wherein the antibody induces cell death of target cells expressing DR5 in vitro in the absence of crosslinking by a secondary antibody and at concentrations less than 1 μg/ml, wherein the antibody induces cell death of target cells expressing DR5 in vivo and wherein the antibody does not bind TRAIL receptor DR4, DcR1 or DcR2.
5. The method of claim 1 , wherein the method is performed in vivo.
6. The method of claim 1 , wherein the method is performed in vitro.
7. The method of claim 4 , wherein the therapeutic agent or agents are anti-inflammatory agents.
8. The method of claim 7 , wherein the anti-inflammatory agent or agents are non-steroidal anti-inflammatory agents.
9. The method of claim 8 , wherein non-steroidal anti-inflammatory agents are COX-1 inhibitors or COX-2 inhibitors.
10. The method of claim 7 , wherein the anti-inflammatory agent or agents are steroidal anti-inflammatory agents.
11. The method of claim 4 , wherein the therapeutic agent or agents are antiviral agents.
12. The method of claim 4 , wherein the therapeutic agent or agents are anti-retroviral agents.
13. The method of claim 4 , wherein the therapeutic agent or agents are anti-opportunistic infection agents.
14. The method of claim 4 , wherein the therapeutic agent or agents are antibiotics.
15. The method of claim 4 , wherein the therapeutic agent or agents are immunosuppressive agents.
16. The method of claim 4 , wherein the therapeutic agent or agents are antimalarial agents.
17. The method of claim 4 , wherein the therapeutic agent or agents are disease modifying anti-rheumatic drugs.
18. The method of claim 4 , wherein the therapeutic agent or agents are cytokines.
19. The method of claim 4 , wherein the therapeutic agent or agents are chemokines.
20. The method of claim 4 , wherein the therapeutic agent or agents are growth factors.
21. The method of claim 4 , wherein the therapeutic agent or agents are selected from the group consisting of chemotherapeutic agents, apoptosis-inducing compounds, members of the TNF family, anti-inflammatory agents, anti-viral, anti-retroviral, anti-opportunistic agents, antibiotics, immunosuppressive agents, immunoglobulins, antimalarial agents, anti-rheumatoid arthritis agents, cytokines, chemokines, growth factors, and second antibody that promotes apoptosis or blocks proliferation of the target cells.
22. The method of claim 4 , wherein the target cell is an abnormally proliferating synovial cell.
23. The method of claim 22 , wherein the synovial cell is a rheumatoid arthritis synovial cell.
24. The method of claim 4 , wherein the target cell is an activated immune cell.
25. The method of claim 24 , wherein the activated immune cell is an activated lymphocyte.
26. The method of claim 4 , wherein the target cell is a neutrophil.
27. The method of claim 4 , wherein the target cell is a virally infected cell.
28. The method of claim 1 , further comprising irradiating the target cells before or after step (a).
29. A method of inhibiting proliferation of target cells expressing DR5, comprising the steps of (a) contacting the target cells with a soluble antibody that specifically binds TRAIL receptor DR5 and (b) contacting the target cells with a therapeutic quantity of one or more therapeutic agents, wherein the antibody is present in an amount sufficient to kill target cells expressing DR5, wherein the antibody induces cell death of target cells expressing DR5 in vitro in the absence of crosslinking by a secondary antibody and at concentrations less than 1 μg/ml, wherein the antibody induces cell death of target cells in vivo, and wherein the antibody does not bind TRAIL receptor DR4, DcR1 or DcR2.
30. The method of claim 29 , wherein the method is performed in vivo.
31. The method of claim 29 , wherein the method is performed in vivo.
32. The method of claim 29 , wherein the therapeutic agent or agents are anti-inflammatory agents.
33. The method of claim 32 , wherein the anti-inflammatory agent or agents are non-steroidal anti-inflammatory agents.
34. The method of claim 33 , wherein non-steroidal anti-inflammatory agents are COX-1 inhibitors or COX-2 inhibitors.
35. The method of claim 32 , wherein the anti-inflammatory agent or agents are steroidal anti-inflammatory agents.
36. The method of claim 29 , wherein the therapeutic agent or agents are antiviral agents.
37. The method of claim 29 , wherein the therapeutic agent or agents are anti-retroviral agents.
38. The method of claim 29 , wherein the therapeutic agent or agents are anti-opportunistic infection agents.
39. The method of claim 29 , wherein the therapeutic agent or agents are antibiotics.
40. The method of claim 29 , wherein the therapeutic agent or agents are immunosuppressive agents.
41. The method of claim 29 , wherein the therapeutic agent or agents are antimalarial agents.
42. The method of claim 29 , wherein the therapeutic agent or agents are anti-rheumatoid arthritis agents.
43. The method of claim 29 , wherein the therapeutic agent or agents are cytokines.
44. The method of claim 29 , wherein the therapeutic agent or agents are chemokines.
45. The method of claim 29 , wherein the therapeutic agent or agents are growth factors.
46. The method of claim 29 , wherein the therapeutic agent or agents are selected from the group consisting of chemotherapeutic agents, apoptosis-inducing compounds, members of the TNF family, anti-inflammatory agents, anti-viral, anti-retroviral, anti-opportunistic agents, antibiotics, immunosuppressive agents, immunoglobulins, antimalarial agents, anti-rheumatoid arthritis agents, cytokines, chemokines, growth factors, and second antibody that promotes apoptosis or blocks proliferation of the target cells.
47. The method of claim 29 , wherein the target cell is an abnormally proliferating synovial cell.
48. The method of claim 47 , wherein the synovial cell is a rheumatoid arthritis synovial cell.
49. The method of claim 29 , wherein the target cell is an activated immune cell.
50. The method of claim 29 , wherein the target cell is an activated lymphocyte.
51. The method of claim 29 , wherein the target cell is a neutrophil.
52. The method of claim 29 , wherein the target cell is a virally infected cell.
53. The method of claim 29 , further comprising irradiating the target cells before or after step (a).
54. A method of treating an inflammatory or autoimmune disease characterized by target cells expressing DR5 in a subject, comprising (a) administering to the subject a soluble antibody that specifically binds TRAIL receptor DR5 and (b) administering to the subject a therapeutic quantity of a therapeutic agent, wherein the antibody is present in an amount sufficient to kill the target cells expressing DR5, wherein the antibody induces cell death of the target cells expressing DR5 in vitro in the absence of crosslinking by a secondary antibody and at concentrations less than 1 μg/ml, wherein the antibody induces cell death of the target cells expressing DR5 in vivo, and wherein the antibody does not bind TRAIL receptor DR4, DcR1 or DcR2.
55. The method of claim 54 , wherein the therapeutic agent or agents are anti-inflammatory agents.
56. The method of claim 55 , wherein the anti-inflammatory agent or agents are non-steroidal anti-inflammatory agents.
57. The method of claim 56 , wherein non-steroidal anti-inflammatory agents are COX-1 inhibitors or COX-2 inhibitors.
58. The method of claim 55 , wherein the anti-inflammatory agent or agents are steroidal anti-inflammatory agents.
59. The method of claim 54 , wherein the therapeutic agent or agents are antiviral agents.
60. The method of claim 54 , wherein the therapeutic agent or agents are anti-retroviral agents.
61. The method of claim 54 , wherein the therapeutic agent or agents are anti-opportunistic infection agents.
62. The method of claim 54 , wherein the therapeutic agent or agents are antibiotics.
63. The method of claim 54 , wherein the therapeutic agent or agents are immunosuppressive agents.
64. The method of claim 54 , wherein the therapeutic agent or agents are antimalarial agents.
65. The method of claim 54 , wherein the therapeutic agent or agents are anti-rheumatoid arthritis agents.
66. The method of claim 54 , wherein the therapeutic agent or agents are cytokines.
67. The method of claim 54 , wherein the therapeutic agent or agents are chemokines.
68. The method of claim 54 , wherein the therapeutic agent or agents are growth factors.
69. The method of claim 54 , wherein the therapeutic agent or agents are selected from the group consisting of chemotherapeutic agents, apoptosis-inducing compounds, members of the TNF family, anti-inflammatory agents, anti-viral, anti-retroviral, anti-opportunistic agents, antibiotics, immunosuppressive agents, immunoglobulins, antimalarial agents, anti-rheumatoid arthritis agents, cytokines, chemokines, growth factors, and second antibody that promotes apoptosis or blocks proliferation of the target cells.
70. The method of claim 54 , further comprising administering to the subject radiation therapy before or after step (a).